TrialJAMA oncology2019

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

XiaoMin Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.